English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Current immunotherapies only benefit a minority of all cancer patients, so it is necessary to develop other strategies to boost patients’ antitumor CD8+ T cell responses. Here, we formulated a liposomal vaccine carrier that selectively delivers tumor antigens and Toll-like receptor agonists to human CD169/Siglec-1+ antigen-presenting cells (APCs) through the incorporation of gangliosides that are natural ligands of CD169. This liposomal vaccine binds to a variety of human CD169+ APCs, including monocyte-derived dendritic cells (moDCs) and the recently described Axl+ DCs. Uptake of the vaccine results in robust cross-presentation and activation of tumor antigen-specific CD8+ T cells. Our findings demonstrate a unique vaccination platform by targeting human CD169+ DCs to stimulate antitumor T cell responses.

Selective tumor antigen vaccine delivery to human CD169 + antigen-presenting cells using ganglioside-liposomes

Selective tumor antigen vaccine delivery to human CD169 ⁺ antigen-presenting cells using ganglioside-liposomes